Kamioka Hiroki, Edaki Kazue, Kasahara Haruka, Tomono Takumi, Yano Kentaro, Ogihara Takuo
Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, Takasaki-shi, Gunma, Japan.
Laboratory of Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki-shi, Gunma, Japan.
J Pharm Pharmacol. 2021 Dec 7;73(12):1609-1616. doi: 10.1093/jpp/rgab051.
Epithelial-mesenchymal transition (EMT) plays a role in cancer metastasis as well as in drug resistance through various mechanisms, including increased drug efflux mediated by P-glycoprotein (P-gp). In this study, we investigated the activation mechanism of P-gp, including its regulatory factors, during EMT in hepatoblastoma-derived HepG2 cells.
HepG2 cells were transfected with SNAI1 using human adenovirus serotype 5 vector. We quantified mRNA and protein expression levels using qRT-PCR and western blot analysis, respectively. P-gp activity was evaluated by uptake assay, and cell viability was assessed by an MTT assay.
P-gp protein expression on plasma membrane was higher in SNAI1-transfected cells than in Mock cells, although there was no difference in P-gp protein level in whole cells. Among the scaffold proteins such as ezrin, radixin and moesin (ERM), only radixin was increased in SNAI1-transfected cells. Uptake of both Rho123 and paclitaxel was decreased in SNAI1-transfected cells, and this decrease was blocked by verapamil, a P-gp inhibitor. The reduced susceptibility of SNAI1-transfected cells to paclitaxel was reversed by elacridar, another P-gp inhibitor.
Increased expression of radixin during SNAI1-induced EMT leads to increased P-gp membrane expression in HepG2 cells, enhancing P-gp function and thereby increasing drug resistance.
上皮-间质转化(EMT)通过多种机制在癌症转移以及耐药性中发挥作用,包括由P-糖蛋白(P-gp)介导的药物外排增加。在本研究中,我们调查了肝母细胞瘤来源的HepG2细胞在EMT过程中P-gp的激活机制,包括其调节因子。
使用人5型腺病毒载体将SNAI1转染到HepG2细胞中。我们分别使用qRT-PCR和蛋白质印迹分析对mRNA和蛋白质表达水平进行定量。通过摄取试验评估P-gp活性,并通过MTT试验评估细胞活力。
虽然全细胞中P-gp蛋白水平没有差异,但在转染SNAI1的细胞中,质膜上的P-gp蛋白表达高于空载体转染细胞。在诸如埃兹蛋白、根蛋白和膜突蛋白(ERM)等支架蛋白中,只有根蛋白在转染SNAI1的细胞中增加。转染SNAI1的细胞中Rho123和紫杉醇的摄取均减少,并且这种减少被P-gp抑制剂维拉帕米阻断。另一种P-gp抑制剂艾拉司群可逆转转染SNAI1的细胞对紫杉醇敏感性的降低。
在SNAI1诱导的EMT过程中根蛋白表达增加导致HepG2细胞中P-gp膜表达增加,增强P-gp功能,从而增加耐药性。